NantHealth Inc (NASDAQ:NH) COO Ronald Allen Louks sold 6,175 shares of the stock in a transaction on Monday, January 8th. The stock was sold at an average price of $3.52, for a total value of $21,736.00. Following the transaction, the chief operating officer now owns 89,690 shares of the company’s stock, valued at $315,708.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Ronald Allen Louks also recently made the following trade(s):
- On Wednesday, December 6th, Ronald Allen Louks sold 5,245 shares of NantHealth stock. The stock was sold at an average price of $3.03, for a total value of $15,892.35.
- On Monday, November 6th, Ronald Allen Louks sold 6,705 shares of NantHealth stock. The stock was sold at an average price of $3.39, for a total value of $22,729.95.
NantHealth Inc (NH) opened at $3.95 on Wednesday. The stock has a market capitalization of $408.40, a PE ratio of -2.22 and a beta of -1.50. NantHealth Inc has a 1-year low of $2.60 and a 1-year high of $10.02. The company has a quick ratio of 2.36, a current ratio of 2.38 and a debt-to-equity ratio of 0.93.
Several analysts have recently commented on NH shares. Jefferies Group restated a “buy” rating and set a $5.00 target price on shares of NantHealth in a report on Thursday, September 28th. Zacks Investment Research upgraded NantHealth from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a report on Thursday, October 12th. BidaskClub cut NantHealth from a “hold” rating to a “sell” rating in a report on Wednesday, October 18th. Finally, Canaccord Genuity decreased their target price on NantHealth from $6.00 to $5.00 and set a “buy” rating on the stock in a report on Friday, November 17th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $8.05.
Institutional investors and hedge funds have recently modified their holdings of the business. Alliancebernstein L.P. acquired a new stake in shares of NantHealth during the second quarter worth about $102,000. GSA Capital Partners LLP acquired a new stake in shares of NantHealth during the second quarter worth about $121,000. Teachers Advisors LLC raised its position in shares of NantHealth by 351.8% during the second quarter. Teachers Advisors LLC now owns 31,578 shares of the company’s stock worth $134,000 after purchasing an additional 24,588 shares during the period. California State Teachers Retirement System raised its position in shares of NantHealth by 132.4% during the second quarter. California State Teachers Retirement System now owns 31,600 shares of the company’s stock worth $134,000 after purchasing an additional 18,000 shares during the period. Finally, Schwab Charles Investment Management Inc. acquired a new stake in shares of NantHealth during the third quarter worth about $180,000. Hedge funds and other institutional investors own 7.10% of the company’s stock.
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.